As a closely watched meeting of cancer researchers gets under way in Chicago on Friday — call it Woodstock for oncologists — a new analysis finds that more cancer therapies have been launched recently than ever before, an unprecedented amount of clinical development is underway, and the spending is rising at double-digit rates.

Specifically, last year saw a record 15 new oncology treatments launched for 17 tumor types, the pipeline of drugs in late-stage development expanded by 19% in 2018 alone and 63% since 2013, and the mean cost for the new medications last year exceeded $175,500. This was less than $209,400 in 2017, but above the nearly $143,600 mean from 2012 to 2018.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy